You have full access to this article via your institution. Figure 1: A family with multiple GISTs and mutation of the KIT gene.

GIST usually occurs in the GI tract, with 80 percent of cases caused by mutations in the KIT gene. The mutations promote the growth and survival of tumor cells. After first-line treatment ...

designed to address both primary and secondary KIT mutations in patients with GIST. Early data from the StrateGIST 1 Phase I/Ib trial demonstrated promising antitumor activity, with an objective ...

GIST typically presents in the GI tract with 80% of cases driven by mutations in the KIT gene that lead to the growth, proliferation, and survival of tumour cells (primary or activating mutations).

IDRX-42 has demonstrated activity against all key primary and secondary KIT mutations, designed to improve outcomes for patients with GIST. Updated clinical data from StrateGIST 1, an ongoing ...

Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST) IDRX-42 offers potential to address all key KIT mutations ...

The first 2 criteria are associated with imatinib's efficacy in CML (BCR-ABL fusion), GIST (KIT or PDGFRA mutation), and HES (FIP1L1-PDGFRA fusion). The information we have for SCLC in regard to ...

The acquisition includes lead molecule, IDRX-42, a highly selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST. GIST typically presents in the GI tract with ...